Effect of Vildagliptin on Adipose Tissue and Skeletal Muscle Metabolism in Obese Patients With Type 2 Diabetes.
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Vildagliptin (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Novartis
- 04 May 2012 Actual end date (1 Apr 2007) added as reported by ClinicalTrials.gov.
- 01 Mar 2009 Results published in Journal of Clinical Endocrinology and Metabolism 94: 846-852, No. 3, Mar 2009
- 11 Sep 2008 Results have been published in the proceedings of the 44th Annual Meeting of the European Association for the Study of Diabetes.